Paricalcitol Trial

• Status: Recruiting
• Trial end date: 2024-04-01

Summary

The trial is designed to establish whether adding a vitamin D analogue, Paricalcitol, to standard chemotherapy treatment, Gemcitabine and Nab-paclitaxel, can improve the outcomes for patients with advanced pancreatic cancer.

• Phase: Phase 2

Details

• Lead Sponsor: Cancer Trials Ireland
• Treatments: Gemcitabine; Paclitaxel